Liraglutide-13C5,15N (TFA)

• UNSPSC Description:

  Liraglutide-13C5,15N (tetraTFA) is the 13C and 15N labeled Liraglutide (HY-P0014)[1]. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus[2].

• Target Antigen:

  GCGR; GLP Receptor; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Others

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/liraglutide-13c5-15n-tetratfa.html

• Purity:

  98.19

• Solubility:

  H2O : 1 mg/mL (adjust pH to 10 with NH3·H2O)

• Molecular Weight:

  3757.16 (free acid)

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported